Clene (NASDAQ: CLNN) , together with its subsidiary Clene Nanomedicine Inc., is preparing to initiate neurofilament biomarker analyses for its lead d ...

Somewhere between recycled meme coins and overhyped layer-2s projects, a new batch of projects is quietly stealing the ...

In this video, Shahzad Raza, MD, discusses safety and efficacy data from Nexicart-2, which studied the use of chimeric antigen receptor T-cell therapy in relapsed or refractory light chain amyloidosis ...

In this video, Shahzad Raza, MD, discusses teclistamab as a potential treatment for patients with relapsed or refractory systemic light chain amyloidosis.“Teclistamab has already been approved in ...

As the dynamic world of cryptocurrencies continues to evolve and mature, savvy investors are looking for the moonshot potential to capitalise on high ROI in ...

Discover the current challenges in diagnosing multiple myeloma and how advances in diagnostic technologies could help ...

Crypto presales are heating up, with Lightchain AI and BlockDAG drawing serious attention from market watchers. Lightchain AI ...

Along with the fact that cryptocurrency is gaining momentum, crypto with 100x potential becomes increasingly appealing to early investors and adopters seeking the next big cryptocurrency projects.

New biomarkers enhance multiple sclerosis (MS) diagnosis, enabling earlier detection and improved patient care, transforming ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...